Bexicaserin

Lundbeck presented data on bexicaserin, a selective 5-HT2C receptor superagonist, at the AES Annual Meeting, highlighting its potential in treating Developmental and Epileptic Encephalopathies (DEEs).

Bexicaserin demonstrated a 59.3% median reduction in countable motor seizures over 12 months in patients with developmental and epileptic encephalopathies (DEEs).

Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN study to evaluate bexicaserin for seizures associated with developmental and epileptic encephalopathies (DEEs).

Longboard Pharmaceuticals has initiated the Phase 3 DEEp OCEAN study to evaluate bexicaserin for seizures associated with Developmental and Epileptic Encephalopathies (DEEs).

Longboard Pharmaceuticals initiated a Phase 3 clinical trial, DEEp SEA, to evaluate bexicaserin in Dravet syndrome patients aged 2-65 years.